Cilostazol

• Description :

  Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM[1][2].

• Product Name Alternative :

  OPC 13013

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Autophagy; Phosphodiesterase (PDE)

• Type :

  Reference compound

• Related Pathways :

  Autophagy; Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cardiovascular Disease; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Cilostazol.html

• Purity :

  99.83

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  O=C1NC2=C(C=C(OCCCCC3=NN=NN3C4CCCCC4)C=C2)CC1

• Molecular Formula :

  C20H27N5O2

• Molecular Weight :

  369.46

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Schr?r K. The pharmacology of cilostazol. Diabetes Obes Metab. 2002 Mar;4 Suppl 2:S14-9.|[2]Minami N, et al. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. Life Sci. 1997;61 (25) :PL 383-9.|[3]Saito S, et al. Cilostazol attenuates hepatic stellate cell activation and protects mice against carbon tetrachloride-induced liver fibrosis. Hepatol Res. 2013 Apr 19.|[4]Ye YL, et al. Cilostazol, a phosphodiesterase 3 inhibitor, protects mice against acute and late ischemic brain injuries.Eur J Pharmacol. 2007 Feb 14;557 (1) :23-31. Epub 2006 Nov 10.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [73963-72-1]